Current and future therapeutic approaches for the treatment of small cell lung cancer

被引：36

作者：

Rossi, Antonio ^{[1
]}

Tay, Rebecca ^{[2
]}

Chiramel, Jaseela ^{[2
]}

Prelaj, Arsela ^{[2
,3
]}

Califano, Raffaele ^{[2
,4
,5
]}

机构：

[1] Sci Inst Res & Hlth Care IRCCS Casa Sollievo dell, Div Med Oncol, San Giovanni Rotondo, Italy

[2] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England

[3] Sapienza Univ Rome, Dept Radiol Pathol & Oncol Sci, Rome, Italy

[4] Manchester Univ NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England

[5] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2018年 / 18卷 / 05期

关键词：

Durvalumab; immunotherapy; ipilimumab; nivolumab; pembrolizumab; rovalpituzumab tesirine; SCLC; second-line; targeted therapy; tremelimumab; PHASE-III TRIAL; PROPHYLACTIC CRANIAL IRRADIATION; PACLITAXEL PLUS BEVACIZUMAB; PLACEBO-CONTROLLED TRIAL; ANTIBODY-DRUG CONJUGATE; DOUBLE-BLIND; OPEN-LABEL; 2ND-LINE TREATMENT; THORACIC RADIOTHERAPY; 1ST-LINE TREATMENT;

D O I：

10.1080/14737140.2018.1453361

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Small-cell lung cancer (SCLC) is a very aggressive disease characterized by a high response rate to first-line chemotherapy, but most patients relapse within 1year with disappointing results to second-line treatments. Chemotherapy has reached a plateau of effectiveness and new therapeutic strategies are needed to change the natural history of SCLC.Areas covered: This review will focus on the current results and the future development of the therapeutic approaches for the treatment of SCLC.Expert commentary: Immunotherapy is becoming a new frontier for the management of SCLC with preliminary interesting results. To date, no targeted drugs have been approved for clinical practice but several novel agents are in an advanced stage of clinical development in SCLC.

引用

页码：473 / 486

页数：14

共 50 条

[41] Current Diagnosis and Management of Small-Cell Lung Cancer
Wang, Shuhang
Zimmermann, Stefan
Parikh, Kaushal
Mansfield, Aaron S.
Adjei, Alex A.
MAYO CLINIC PROCEEDINGS, 2019, 94 (08) : 1599 - 1622
[42] Targeted therapy for non-small-cell lung cancer: past, present and future
Forde, Patrick M.
Ettinger, David S.
EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (06) : 745 - 758
[43] Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors
Reddy, Haritha G.
Qin, Angel
Kalemkerian, Gregory P.
EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (03) : 353 - 366
[44] Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions
Qin, Qin
Li, Baosheng
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (04) : 743 - 750
[45] Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
Martin, Claudio
Enrico, Diego
FRONTIERS IN ONCOLOGY, 2022, 12
[46] Immunotherapy era in the treatment of small cell lung cancer
Araz, Murat
Karakurt Eryilmaz, Melek
MEDICAL ONCOLOGY, 2021, 38 (07)
[47] Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Lim, Sun Min
Hong, Min Hee
Kim, Hye Ryun
IMMUNE NETWORK, 2020, 20 (01)
[48] Advancements in small cell lung cancer
Lee, Jung-hoon
Saxena, Ashish
Giaccone, Giuseppe
SEMINARS IN CANCER BIOLOGY, 2023, 93 : 123 - 128
[49] Small Cell Lung Cancer A Review
Kim, So Yeon
Park, Henry S.
Chiang, Anne C.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2025,
[50] Immunotherapy for Small Cell Lung Cancer: Established Applications and Novel Approaches
Scott, Susan C.
Hann, Christine L.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (10) : 654 - 663

← 1 2 3 4 5 →